Lupus Nephritis

Kidney Disease: Improving Global Outcomes has released a revised clinical practice guideline for the treatment of lupus nephritis.

The FDA has granted fast track designation for an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate to treat those with refractory progressive multiple sclerosis, according to the manufacturer.

The FDA has granted fast track designation for KYV-101, an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, to treat myasthenia gravis.

An organ procurement organization and a patient support and advocacy group will have floats in the 2024 Tournament of Roses Parade promoting organ donation and to spread awareness about kidney health screening.

The acceptable threshold for glucocorticoid use for lupus maintenance therapy should be 5 mg per day prednisone equivalent or less, according to the updated 2023 EULAR recommendations for the management of systemic lupus erythematosus.

SAN DIEGO — Improving hydroxychloroquine use and reducing glucocorticoid exposure are among the top priorities of the Healthy People with Lupus 2030 initiative, which aims to address care disparities, said a speaker at ACR Convergence 2023.

SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.

SAN DIEGO — Obinutuzumab use increases the chances of achieving complete renal response and lowers the risk for kidney-related events and time to flare in lupus nephritis, according to data presented at ACR Convergence 2023.

The FDA has granted breakthrough therapy designation for felzartamab, an investigational antibody to treat primary membranous nephropathy.

Long-term voclosporin is safe and efficacious for the treatment of lupus nephritis over 3 years, according to data published in Arthritis & Rheumatology.